Xtant Medical Holdings, Inc. (XTNT)
XTNT Stock Price Chart
Explore Xtant Medical Holdings, Inc. interactive price chart. Choose custom timeframes to analyze XTNT price movements and trends.
XTNT Company Profile
Discover essential business fundamentals and corporate details for Xtant Medical Holdings, Inc. (XTNT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
1 Jul 2010
Employees
217.00
Website
https://www.xtantmedical.comCEO
Sean E. Browne
Description
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
XTNT Financial Timeline
Browse a chronological timeline of Xtant Medical Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
Revenue estimate is $32.70M.
Earnings released on 12 Aug 2025
EPS came in at $0.02 surpassing the estimated -$0.01 by +300.00%, while revenue for the quarter reached $35.41M , beating expectations by +13.50%.
Earnings released on 12 May 2025
EPS came in at $0.00 surpassing the estimated -$0.01 by +104.00%, while revenue for the quarter reached $32.90M , beating expectations by +5.39%.
Earnings released on 6 Mar 2025
EPS came in at -$0.02 falling short of the estimated -$0.01 by -100.00%, while revenue for the quarter reached $31.51M , missing expectations by -0.89%.
Earnings released on 12 Nov 2024
EPS came in at -$0.04 falling short of the estimated -$0.03 by -60.00%, while revenue for the quarter reached $27.94M , missing expectations by -12.13%.
Earnings released on 8 Aug 2024
EPS came in at -$0.03 falling short of the estimated -$0.02 by -50.00%, while revenue for the quarter reached $29.94M , beating expectations by +4.33%.
Earnings released on 15 May 2024
EPS came in at -$0.03 falling short of the estimated -$0.02 by -100.00%, while revenue for the quarter reached $27.87M , beating expectations by +8.24%.
Earnings released on 1 Apr 2024
EPS came in at -$0.03 falling short of the estimated -$0.03 by -20.00%, while revenue for the quarter reached $28.11M , beating expectations by +5.87%.
Earnings released on 9 Nov 2023
EPS came in at $0.07 surpassing the estimated $0.01 by +449.88%, while revenue for the quarter reached $25.02M , missing expectations by -6.65%.
Earnings released on 1 Aug 2023
EPS came in at -$0.02 matching the estimated -$0.02, while revenue for the quarter reached $20.23M , beating expectations by +3.75%.
Earnings released on 4 May 2023
EPS came in at -$0.02 falling short of the estimated -$0.02 by -33.33%, while revenue for the quarter reached $17.94M , beating expectations by +18.05%.
Earnings released on 7 Mar 2023
EPS came in at -$0.02 , while revenue for the quarter reached $15.27M , beating expectations by +8.95%.
Earnings released on 3 Nov 2022
EPS came in at -$0.03 , while revenue for the quarter reached $14.46M , beating expectations by +3.19%.
Earnings released on 4 Aug 2022
EPS came in at -$0.02 , while revenue for the quarter reached $15.28M , beating expectations by +9.00%.
Earnings released on 5 May 2022
EPS came in at -$0.03 , while revenue for the quarter reached $12.96M , missing expectations by -7.53%.
Earnings released on 8 Mar 2022
EPS came in at -$0.03 , while revenue for the quarter reached $13.97M , missing expectations by -0.32%.
Earnings released on 12 Nov 2021
EPS came in at -$0.02 , while revenue for the quarter reached $13.78M , missing expectations by -1.70%.
Earnings released on 5 Aug 2021
EPS came in at -$0.01 , while revenue for the quarter reached $14.98M , beating expectations by +6.85%.
Earnings released on 11 May 2021
EPS came in at -$0.00 , while revenue for the quarter reached $12.54M .
Earnings released on 24 Feb 2021
EPS came in at -$0.01 , while revenue for the quarter reached $14.02M .
Earnings released on 29 Oct 2020
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $14.02M , missing expectations by -9.08%.
XTNT Stock Performance
Access detailed XTNT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.